Technical Analysis for SAR - Sareum Holdings Plc

Grade Last Price % Change Price Change
F 10.75 -25.86% -3.75
SAR closed down 25.86 percent on Thursday, March 28, 2024, on 18.72 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Boomer Sell Setup Bearish Swing Setup -25.86%
NR7 Range Contraction -25.86%

   Recent Intraday Alerts

Alert Time
5x Volume Pace about 20 hours ago
3x Volume Pace about 20 hours ago
2x Volume Pace about 20 hours ago
1.5x Volume Pace about 20 hours ago
10x Volume Pace about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sareum Holdings Plc Description

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Cancer Disease Branches Of Biology Drugs Diseases Biology Radio Therapy Autoimmune Diseases Blood Disorders Cancers Skills Enzymes Rheumatoid Arthritis Acute Myeloid Leukemia Arthritis Chemotherapy Medicinal Chemistry Psoriasis Acute Lymphoblastic Leukemia Head And Neck Cancers Inflammatory Disorders Kinase Leukemia Radiotherapy Tyrosine Kinase

Is SAR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 149.0
52 Week Low 10.0
Average Volume 384,412
200-Day Moving Average 68.71
50-Day Moving Average 34.96
20-Day Moving Average 23.91
10-Day Moving Average 16.23
Average True Range 4.93
RSI (14) 20.00
ADX 47.5
+DI 5.23
-DI 31.21
Chandelier Exit (Long, 3 ATRs) 25.21
Chandelier Exit (Short, 3 ATRs) 24.79
Upper Bollinger Bands 41.16
Lower Bollinger Band 6.67
Percent B (%b) 0.12
BandWidth 144.24
MACD Line -6.78
MACD Signal Line -6.13
MACD Histogram -0.6537
Fundamentals Value
Market Cap 7.55 Million
Num Shares 70.3 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -215.00
Price-to-Sales 4491.97
Price-to-Book 24.38
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.05
Resistance 3 (R3) 14.17 13.18 13.50
Resistance 2 (R2) 13.18 12.34 13.13 13.32
Resistance 1 (R1) 11.97 11.82 11.48 11.85 13.13
Pivot Point 10.98 10.98 10.74 10.93 10.98
Support 1 (S1) 9.77 10.14 9.28 9.65 8.37
Support 2 (S2) 8.78 9.62 8.73 8.18
Support 3 (S3) 7.57 8.78 8.00
Support 4 (S4) 7.45